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The Strategy Group of the United Kingdom Co-ordinating
Committee on Cancer Research (UKCCCR) held a workshop on
20 November 1997 to consider the question of ‘Improvements in
Patient Access to New Anti-Cancer Medicines’. The Chairman was
Professor Sir William Asscher (Chairman, UKCCCR) and the
meeting was attended by representatives of the Medical Research
Council (MRC), Cancer Research Campaign (CRC), Imperial
Cancer Research Fund (ICRF) and Leukaemia Research Fund
(LRF), together with a number of invited speakers and rapporteurs.
Dr Peter Twentyman (Executive Secretary, UKCCCR) in intro-
ducing the Workshop expressed the view that there was, among
oncologists in the UK, a large amount of goodwill and enthusiasm
for clinical trials, but a strong feeling that a considerable obstacle
course lay in the path of those wishing to participate. The steps
involved in getting a trial funded and running are widely regarded
as excessively burdensome and getting worse. Even when trials are
open to accrual, heterogeneity with respect to ethical approval and
local funding of support costs has proved problematic. New
arrangements for National Health Service (NHS) support of clinical
trials will, however, operate from April 1998 and the impact of
these will be closely monitored. Difficulties have arisen when
company-sponsored trials have competed for accrual with acad-
emic-based trials including quality of life and health economic
assessment. This could result in difficulties for the determination of
cost-effectiveness of new therapies. There have been various recent
examples of cancer service providers being unable or unwilling to
meet the costs of expensive new anti-cancer treatments.
Professor Paul Workman (Institute of Cancer Research, Sutton)
described the importance of collaboration between academia and
industry in terms of new drug development. He discussed the
commercial issues driving R&D strategy within the pharmaceu-
tical industry and the need to align research to commercial objec-
tives. He went on to describe recent advances in drug discovery
and the need for speed in the development of innovative agents.
Professor Lewis Smith (MRC Toxicology Unit, Leicester)
believed that one of the most important blocks to getting new
drugs through the system is getting the drug into man in the first
place. He emphasized the need for early ‘proof of principle’ and he
believed that there was a need for a more pragmatic and rational
approach to new anti-cancer drugs.
Professor Michael Rawlins [Chairman, Committee on Safety of
Medicines (CSM)] explained that, in his view, there was a
tendency for regulatory guidelines to examine the past rather than
the future. He thought that we are rapidly moving into an era of
Europe-wide drug licensing and that current European guidelines
are rather limited in scope. In future, he believed that constraints
would be placed on the use of licensed medicines because of finan-
cial and other reasons. Professor Hilary Calvert (University of
Newcastle) agreed that the question of ‘Is this agent clinically
useful’ was as important as ‘Can it be safely administered’. This
applied particularly to supportive agents such as colony-stimu-
lating factors. He also felt that the CSM should have the power to
insist that a requirement for further studies following granting of a
phase II licence should be enforced.
Dr Martyn Evans (University of Wales) discussed the advent of
the new system of Multicentre Research Ethics Committees
(MREC) based on regions. There were a number of advantages to
the new system including the inclusion of specified ‘turnaround
times’ but also some disadvantages. In the new system, the Local
Research Ethics Committees (LRECs) would be able to request
minor local amendments to the patient information sheet or
consent form but not the protocol. Nevertheless, an LREC may
draw to the attention of an MREC Chairman serious concerns
regarding the protocol, which that Chairman must consider and
may refer the application back to the MREC for reconsideration.
The LRECs’ decision-making powers would be restricted to
whether or not a trial should proceed locally. He felt strongly that
the medical community should request a clearer ‘spelling-out’ of
the local criteria upon which the LRECs would be able to base
their judgement. Mrs Jennifer Blunt (Chair, North West MREC)
thought that the old framework had not worked well. The problem
was not with the standard of review but with the variability in the
system. She pointed out the new system was not ‘hierarchical’ but
that MRECs and LRECs would have separate and complementary
duties. In the discussion, there was a strong view that specializa-
tion by MRECs might have been a better system. It was noted that
the new system would be formally evaluated in 1999.
Dr Peter Brambleby (Consultant in Public Health, East Norfolk
Health Authority) showed the distribution of expenditure of a
typical health authority with the majority of spend on chronic
disease, not acute specialities like oncology. NHS trusts usually
recoup the cost of cancer drugs through prices for episodes of care
in oncology. Even then, the total drugs budget of a typical district
general hospital is around 5%. Appraisal of new drugs by health
authorities follows a checklist which includes: evidence of clini-
cally significant effect, guidelines for use including clinical
responsibility, financial impact, added cost relative to added
benefit, priority status relative to other demands, consultation and
a final decision. A tension existed between the drive for local
sensitivity and responsiveness in health care commissioning,
which can introduce variation in availability of services, and
simultaneous concern about widening inequalities in access across
the country. He called on the help of the research community in the
areas of epidemiology, effectiveness, economics, education and
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ethics. Health authorities were busy places and the ‘right decisions
needed to be easy decisions’. Professor Stan Kaye (University of
Glasgow) believed that setting funding priorities for new anti-
cancer drugs could be very difficult. Oncologists should press for
increased funding where a survival benefit is clear, but acknowl-
edge the need to restrict usage to approved centres and/or clini-
cians using agreed guidelines. A particular problem arose when a
drug gave clear clinical benefit in the absence of survival benefit.
Quality of life measures were then extremely important and
prospective randomized trials essential.
Professor Nick Thatcher (University of Manchester) analysed
factors which disposed towards success or failure in cancer
clinical trials. Successful trials were characterized by attractive
protocol design, enthusiasm and commitment by a specific co-
ordinator and the presence of adequate funding. Companies were
increasingly reluctant to sponsor trials in the UK because of rela-
tively high costs in comparison with other countries. Whereas, for
example, in the United States and in mainland Europe, large
amounts of money were being invested into trials of novel drug
combinations in non-small-cell lung cancer, there were no such
trials in the UK. Furthermore, the overall NHS budget for cyto-
toxic drugs is very low compared with that for other types of
drugs. Professor Thatcher felt that there was no lack of innovative
ideas for trials in the UK, but major bureaucratic hurdles and inad-
equate funding were major disincentives for progress. Professor
David Kerr (University of Birmingham) emphasized the impor-
tance of establishing a strong clinical trials network within the
country. He felt confident that there is the capacity within the UK
for the carrying out of large, innovative phase III trials. The new
system of central subventions for burdensome excess treatment
costs should prove helpful. Setting of targets for cancer centres
and units in terms of trial participation could be an important
element of continued accreditation.
Professor Peter Selby (Clinical Director, Imperial Cancer
Research Fund) emphasized the importance that should be
attached to ensuring equality of access to all aspects of cancer
medicine. He gave examples of dramatic inequalities which
currently exist. Implementation of the Calman–Hine proposals
was currently very ‘patchy’. There is a clear need for improve-
ments in the number of cancer specialists in the UK. Demographic
changes over the next few years meant that the cost of imple-
menting Calman–Hine would be approximately £35–40 million
per year in 5 years’ time. Dr John Toy (Director of Clinical
Programmes, Cancer Research Campaign) emphasized that treat-
ments can only be accessed by clinicians, and the harder clinicians
pushed the more likely expensive treatments would be made avail-
able. He agreed that inequity of treatment was a major problem
and that this was due to seemingly idiosyncratic clinical practice
as well as financial constraints. There may need to be a greater
emphasis on protocol-driven care based on findings that patients
entered into clinical trials protocols tend to have better outcomes.
In conclusion, it was felt that the Workshop had been useful in
highlighting a number of areas in which increased pressure from
the cancer clinical community could be productive in improving
access to new therapies.
Specific attention should be given to:
(a) Lobbying for the best available therapies to be made
uniformly available to all subsections of the community.
(b) Participation in clinical trials to be a prerequisite for centres
and units to become accredited and maintain their status under
the Calman–Hine arrangement.
(c) Making strong bids whenever possible for money from the
Lottery Opportunities Fund to support better cancer treat-
ments and a uniformity of approach throughout the UK.